Hybrid immunity and protection against infection during the Omicron wave in Malta

References

• Cuschieri S, Agius S, Souness J, et al. The fastest national COVID vaccination in Europe – Malta’s strategies. Health Sci Rev. 2021;1:100001, doi:10.1016/j.hsr.2021.100001.
   PubMedGoogle Scholar
• ECDC. COVID-19 vaccine tracker | European centre for disease prevention and control. Published; 2022. [cited 2022 Jul 12]. Available from: https://vaccine tracker.ecdc.europa.eu/public/extensions/covid-19/vaccine-tracker.html#uptake-tab.
   Google Scholar
• Vaccination Registry System M. COVID-19 in Malta – open dataset. Published online July 6, 2022. [cited 2022 Jul 20]. Available from: https://github.com/COVID19-Malta/COVID19-Data/blob/fdcfca23701eb1567577b09aeec1f7d2f41a1da2/COVID-19%20Malta%20-%20Vaccination%20Data.csv.
   Google Scholar
• GISAID. Hcov-19 variants dashboard. GISAID. Published online November 2022. Available from: https://gisaid.org/hcov-19-variants-dashboard/.
   Google Scholar
• Lewnard JA, Hong VX, Patel MM, et al. Clinical outcomes associated with Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in Southern California. Nat Med. 2022;28:1933–1943. https://doi.org/10.1038/s41591-022-01887-z
   PubMed Web of Science ®Google Scholar
• Davies MA, Kassanjee R, Rousseau P, et al. Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth wave compared with previous waves in the Western Cape Province, South Africa. MedRxiv. Published online 2022.
   Google Scholar
• Andrews N, Stowe J, Kirsebom F, et al. COVID-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. N Engl J Med. 2022;386(16):1532–46. doi:10.1056/NEJMoa2119451
   PubMed Web of Science ®Google Scholar
• Andeweg SP, de Gier B, Eggink D, et al. Protection of COVID-19 vaccination and previous infection against Omicron BA.1, BA.2 and delta SARS-CoV-2 infections. Nat Commun. 2022;13:4738. doi:10.1101/2022.02.06.22270457
   PubMed Web of Science ®Google Scholar
• Chen J, Wang R, Gilby NB, et al. Omicron variant (B. 1.1. 529): infectivity, vaccine breakthrough, and antibody resistance. J Chem Inf Model. 2022;62(2):412–422.
   PubMed Web of Science ®Google Scholar
• Feikin DR, Higdon MM, Abu-Raddad LJ, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet. 2022;399(10328):924–944.
   PubMed Web of Science ®Google Scholar
• Altarawneh HN, Chemaitelly H, Ayoub H, et al. Effects of previous infection and vaccination on symptomatic omicron infections. N Engl J Med. 2022;387(1):21–34.
   PubMed Web of Science ®Google Scholar
• WHO. Tracking SARS-CoV-2 variants. Published 2022. [cited 2022 Jul 18]. Available from: https://www.who.int/activities/tracking-SARS-CoV-2-variants.
   Google Scholar
• Andrews N, Tessier E, Stowe J, et al. Duration of protection against mild and severe disease by COVID-19 vaccines. N Engl J Med. 2022;386(4):340–350. doi:10.1056/NEJMoa2115481.
   PubMed Web of Science ®Google Scholar
• Nevejan L, Cuypers L, Laenen L, et al. Early SARS-CoV-2 reinfections within 60 days highlight the need to consider antigenic variations together with duration of immunity in defining retesting policies. medRxiv. Published online 2022.
   Google Scholar
• National Statistics Office Malta. Malta: World Population Day. National Statistics Office Malta; 2021:13. [cited 2022 Jun 30]. Available from: https://nso.gov.mt/en/News_Releases/Documents/2021/07/News2021_122.pdf.
   Google Scholar
• Barda N, Dagan N, Cohen C, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet. 2021;398(10316):2093–2100. doi:10.1016/S0140-6736(21)02249-2.
   PubMed Web of Science ®Google Scholar
• Firinu D, Perra A, Campagna M, et al. Evaluation of antibody response to BNT162b2 mRNA COVID-19 vaccine in patients affected by immune-mediated inflammatory diseases up to 5 months after vaccination. Clin Exp Med. 2021;22:477–485. doi:10.1007/s10238-021-00771-3.
   PubMed Web of Science ®Google Scholar
• El Sahly HM, Baden LR, Essink B, et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. N Engl J Med. 2021;385(19):1774–85. doi:10.1056/NEJMoa2113017
   PubMed Web of Science ®Google Scholar
• Katzourakis A. COVID-19: endemic doesn’t mean harmless. Nature. 2022;601(7894):485–485. doi:10.1038/d41586-022-00155-x.
   PubMed Web of Science ®Google Scholar
• Al-Tawfiq JA, Chu DT, Hoang VT, et al. From pandemicity to endemicity: the journey of SARS-CoV-2. J Epidemiol Glob Health. 2022;12:147–149. doi:10.1007/s44197-022-00046-4
   PubMed Web of Science ®Google Scholar
• Tartof SY, Slezak JM, Fischer H, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021;398(10309):1407–1416.
   PubMed Web of Science ®Google Scholar
• Gupta RK, Topol EJ. COVID-19 vaccine breakthrough infections. Science. 2021;374(6575):1561–1562. doi:10.1126/science.abl8487.
   PubMed Web of Science ®Google Scholar
• Levin EG, Lustig Y, Cohen C, et al. Waning immune humoral response to BNT162b2 COVID-19 vaccine over 6 months. New England J Medicine. 2021;385(24):e84.
   PubMed Web of Science ®Google Scholar
• Ferdinands JM, Rao S, Dixon BE, et al. Waning 2-dose and 3-dose effectiveness of mRNA vaccines against COVID-19–associated emergency department and urgent care encounters and hospitalizations among adults during periods of delta and omicron variant predominance – VISION network, 10 states, August 2021–January 2022. MMWR Morb Mortal Wkly Rep. 2022;71(7):255–263. doi:10.15585/mmwr.mm7107e2.
   PubMed Web of Science ®Google Scholar
• Pilz S, Theiler-Schwetz V, Trummer C, et al. SARS-CoV-2 reinfections: overview of efficacy and duration of natural and hybrid immunity. Environ Res. 2022;209:112911. doi:10.1016/j.envres.2022.112911.
   PubMed Web of Science ®Google Scholar
• Gallo Marin B, Aghagoli G, Lavine K, et al. Predictors of COVID-19 severity: a literature review. Rev Med Virol. 2021;31(1):1–10.
   PubMed Web of Science ®Google Scholar
• Pijls BG, Jolani S, Atherley A, et al. Demographic risk factors for COVID-19 infection, severity, ICU admission and death: a meta-analysis of 59 studies. BMJ Open. 2021;11(1):e044640.
   PubMed Web of Science ®Google Scholar
• Zinatizadeh MR, Zarandi PK, Zinatizadeh M, et al. Efficacy of mRNA, adenoviral vector, and perfusion protein COVID-19 vaccines. Biomed Pharmacother. 2022;146:112527. doi:10.1016/j.biopha.2021.112527.
   PubMed Web of Science ®Google Scholar
• Chiu NC, Chi H, Tu YK, et al. To mix or not to mix? A rapid systematic review of heterologous prime–boost COVID-19 vaccination. Expert Rev Vaccines. 2021;20(10):1211–1220. doi:10.1080/14760584.2021.1971522.
   PubMed Web of Science ®Google Scholar
• Rashedi R, Samieefar N, Masoumi N, et al. COVID-19 vaccines mix-and-match: The concept, the efficacy and the doubts. J Med Virol. 2022;94(4):1294–1299. doi:10.1002/jmv.27463.
   PubMed Web of Science ®Google Scholar
• Bhattacharya M, Sharma AR, Dhama K, et al. Hybrid immunity against COVID-19 in different countries with a special emphasis on the Indian scenario during the omicron period. Int Immunopharmacol. 2022;108:108766, doi:10.1016/j.intimp.2022.108766.
   PubMed Web of Science ®Google Scholar
• Goldberg Y, Mandel M, Bar-On YM, et al. Protection and waning of natural and hybrid COVID-19 immunity. MedRxiv. Published online 2021.
   Google Scholar
• Epsi NJ, Richard SA, Lindholm DA, et al. Understanding ‘hybrid immunity’: comparison and predictors of humoral immune responses to SARS-CoV-2 infection and COVID-19 vaccines. Clin Infect Dis. Published online 2022.
   Web of Science ®Google Scholar
• Bignucolo A, Scarabel L, Mezzalira S, et al. Sex disparities in efficacy in COVID-19 vaccines: a systematic review and meta-analysis. Vaccines (Basel). 2021;9(8):825. doi:10.3390/vaccines9080825.
   PubMed Web of Science ®Google Scholar
• Bar-On YM, Goldberg Y, Mandel M, et al. Protection by a fourth dose of BNT162b2 against omicron in Israel. N Engl J Med. 2022;386(18):1712–1720. doi:10.1056/NEJMoa2201570.
   PubMed Web of Science ®Google Scholar